GlassScriptPhysician profile
Sharnel M Reed
NPI 1609317908
$7,607.23
in general payments reported to CMS, 2019-2025
32 companies · $2,609 in 2025
The $2,609 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $559 · 2022: $807 · 2023: $1,653 · 2024: $1,979 · 2025: $2,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,018 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,018.17 |
| Education | $222.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,245.86 | 2023-2025 | Zoryve |
| Abbvie INC. | $1,024.74 | 2021-2025 | |
| Janssen Biotech, INC. | $727.68 | 2021-2025 | Tremfya |
| Genzyme Corporation | $512.90 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $425.19 | 2023-2025 | Sotyktu |
| Allergan, INC. | $422.15 | 2021-2022 | |
| Incyte Corporation | $343.01 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $318.21 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $302.41 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $281.26 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $264.26 | 2021-2025 | Nemluvio, Epsolay, Aklief |
| Pfizer INC. | $262.87 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $204.56 | 2021-2025 | Ilumya |
| Dermavant Sciences, INC. | $161.75 | 2022-2024 | Vtama |
| Lilly USA, LLC | $157.12 | 2023-2025 | Olumiant, Taltz, Ebglyss |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $136.68 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $123.26 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $120.08 | 2022 | |
| Journey Medical Corporation | $100.10 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.93 | 2023-2024 | Spevigo |
| Leo Pharma INC. | $67.66 | 2021-2025 | Adbry, Anzupgo |
| Verrica Pharmaceuticals INC. | $66.76 | 2025 | Ycanth |
| Organon LLC | $48.31 | 2025 | |
| Organogenesis INC. | $42.56 | 2025 | Affinity |
| Epi Health, LLC | $37.32 | 2021 | |
| Smith+Nephew, INC. | $30.51 | 2025 | Collagenase Santyl |
| Ucb, INC. | $29.13 | 2025 | Bimzelx |
| Mallinckrodt Hospital Products INC. | $22.72 | 2025 | Acthar |
| Convatec INC. | $15.43 | 2023 | |
| Paratek Pharmaceuticals, INC. | $14.52 | 2025 | Nuzyra |
| Dermira, INC. | $13.53 | 2021 | |
| Nabriva Therapeutics, Plc | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharnel Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.